[Federal Register Volume 76, Number 111 (Thursday, June 9, 2011)]
[Notices]
[Pages 33794-33795]
[FR Doc No: 2011-14228]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-64597; File No. SR-CHX-2011-10]

Self-Regulatory Organizations; Chicago Stock Exchange,
Incorporated; Notice of Filing and Immediate Effectiveness of Proposed
Rule Change Related to Orders That Are Eligible for Entry to the
Exchange's Matching System

 June 3, 2011.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that, on May 31, 2011, the Chicago Stock Exchange, Incorporated
(``Exchange'' or ``CHX'') filed with the Securities and Exchange
Commission (the ``Commission'') the proposed rule change as described
in Items I and II below, which Items have been prepared by the
Exchange. The Exchange filed the proposal as a ``non-controversial''
proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act
\3\ and Rule 19b-4(f)(6) thereunder.\4\ The Commission is publishing
this notice to solicit comments on the proposed rule change from
interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \4\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend CHX Article 20, Rule 4 which governs
orders that are eligible for entry to the Exchange's Matching System.
The text of this proposed rule change is available on the Exchange's
Web site at (http://www.chx.com), at the Exchange's Office of the
Secretary, and in the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the CHX included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received regarding the proposal. The text of
these statements may be examined at the places specified in Item IV
below. The CHX has prepared summaries, set forth in sections A, B and C
below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange is proposing to amend CHX Article 20, Rule 4, which
governs the basic requirements for order eligibility in the CHX
Matching System.\5\ The rule is essentially broken down into two parts:
(i) Basic requirements for an order to be deemed acceptable by the
Matching System and (ii) order types and indications that are eligible
for entry to and accepted by the Matching System. The Exchange is
proposing to amend CHX Article 20, Rule 4 as it pertains to order
eligibility by providing the Exchange with the ability to determine on
an order type by order type basis which orders and indications are
eligible for entry to the Matching System.\6\
---------------------------------------------------------------------------

    \5\ The CHX Matching System is our core trading facility. See
CHX Article 20 generally for the operation of the CHX Matching
System.
    \6\ The Chicago Board Options Exchange, Incorporated (``CBOE'')
has similar rules that give the exchange the authority to determine
which orders are eligible for its systems. See CBOE Rule 7.4
relating to obligations for orders. Under CBOE Rule 7.4(b)(iii),
orders that are eligible to be placed with an Order Book Official or
directly into the electronic book include such orders as may be
designated by the Exchange. See also CBOE Rule 43.2 relating to the
types of orders handled on the CBOE's Screen Based Trading System
(``SBT System''). Under CBOE Rule 43.2(a), the Exchange has the
discretion to determine which orders under the rule may be
accommodated on the SBT System.
---------------------------------------------------------------------------

    Currently, all orders sent to the Matching System must meet the
requirements specified in CHX Article 20, Rule 4(a) and shall be
automatically rejected if they do not meet those requirements. In
addition, the Matching System will only accept the order types and
order indications that are defined in CHX Article 20, Rule 4(b).
Currently, by rule the Matching System must accept each and every order
type and order indication found in CHX Article 20, Rule 4(b). If the
Exchange determines that a certain order type (or order indication)
should no longer be eligible for entry into the Matching System, the
Exchange would need to submit a formal rule change with the Securities
and Exchange Commission (``SEC'') pursuant to Section 19(b)(1) of the
Act \7\ and Rule 19b-4 thereunder,\8\ in order to eliminate such order
type from the rule.
---------------------------------------------------------------------------

    \7\ 15 U.S.C. 78s(b)(1).
    \8\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

    For purposes of efficiency and flexibility in determining which
orders shall be eligible for entry to the Matching System (at any point
in time), the Exchange is proposing to amend its rule to give the
Exchange the ability to turn an order type under CHX Article 20, Rule
4(b) on or off without having to file a formal rule change with the
SEC.\9\ By making this change, the Exchange will be able to designate
on an order type by order type basis which orders under CHX Article 20,
Rule 4(b) will be eligible for entry to and accepted by the Matching
System. Under the proposal, when the Exchange determines to make an
order eligible or ineligible under the rule (e.g., turns an order on or
off), the Exchange will provide notification of such change to its
market participants through the issuance of a regulatory circular and
identify which orders under the rule are eligible for entry to the
Matching System. Such notification will be provided by the Exchange in
a manner which will give reasonable advance notice to its market
participants. For example, the Exchange will not designate an order
type eligible or ineligible intraday.
---------------------------------------------------------------------------

    \9\ The ability to turn an order on or off is only applicable to
those orders found in CHX Article 20, Rule 4(b). If the Exchange
determines to introduce a new order type not found in the rule, the
Exchange will submit such proposal through the rule filing process
to the SEC for consideration and approval.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposed rule change is consistent
with Section 6(b) of the Act in general,\10\ and furthers the
objectives of Section 6(b)(5) in particular,\11\ in that it is designed
to promote just and equitable principles of trade, to foster
cooperation and coordination with persons engaged in facilitating
transaction in securities, to remove impediments and perfect the
mechanisms of a free and open market, and, in general, to protect
investors and the public interest by giving the Exchange the ability to
determine which orders under CHX Article 20, Rule 4(b) are eligible for
entry to and accepted by the Exchange's Matching System.
---------------------------------------------------------------------------

    \10\ 15 U.S.C. 78f(b).
    \11\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The flexibility to turn certain order types on and off will give
the Exchange the ability to accept orders into its Matching System that
is consistent with order types that are eligible at other market
centers. This flexibility will be especially beneficial when the
Exchange implements a routing system that routes unexecuted orders to
other market centers. For example, certain CHX order types defined in
CHX Article 20, Rule 4(b) may not be acceptable at other exchanges and
by being able to turn an order on or off will give the Exchange

the ability to address these non-compatibility issues without having to
formally remove an order type from its rules. And as previously noted,
the proposed process of determining order eligibility for purposes of
the CHX Matching System is consistent with CBOE's rules that address
order eligibility on its systems. Lastly, the Exchange will also
provide sufficient notice of any change in order eligibility through
the issuance of a regulatory circular and such notification will be
done in a manner which will provide reasonable advance notice to its
market participants.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments Regarding the
Proposed Rule Change Received From Members, Participants or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not significantly
affect the protection of investors or the public interest, does not
impose any significant burden on competition, and, by its terms, does
not become operative for 30 days from the date on which it was filed,
or such shorter time as the Commission may designate, it has become
effective pursuant to Section 19(b)(3)(A) of the Act \12\ and Rule 19b-
4(f)(6) thereunder.\13\
---------------------------------------------------------------------------

    \12\ 15 U.S.C. 78s(b)(3)(A).
    \13\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii)
requires the Exchange to give the Commission written notice of the
Exchange's intent to file the proposed rule change, along with a
brief description and text of the proposed rule change, at least
five business days prior to the date of filing of the proposed rule
change, or such shorter time as designated by the Commission. The
Exchange has satisfied the five-day prefiling requirement.
---------------------------------------------------------------------------

    The Exchange has requested that the Commission waive the 30-day
operative delay. The Commission believes that waiver of the operative
delay is consistent with the protection of investors and the public
interest because the proposal is similar to the rules of another
exchange that have been approved by the Commission,\14\ and will allow
the Exchange to address order compatibility before it implements
changes to its routing system. Therefore, the Commission designates the
proposal operative upon filing.\15\
---------------------------------------------------------------------------

    \14\ See supra note 6.
    \15\ For purposes only of waiving the 30-day operative delay,
the Commission has considered the proposed rule's impact on
efficiency, competition, and capital formation. See 15 U.S.C.
78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-CHX-2011-10 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-CHX-2011-10. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of the filing also will be available for
inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-CHX-2011-10 and should be
submitted on or before June 30, 2011.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\16\
---------------------------------------------------------------------------

    \16\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Cathy H. Ahn,
Deputy Secretary.
[FR Doc. 2011-14228 Filed 6-8-11; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 85, Number 185 (Wednesday, September 23, 2020)]
[Notices]
[Page 59804]
[FR Doc No: 2020-21023]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-1482]

Cannabidiol and Other Cannabinoids: Sex and Gender Differences in
Use and Responses; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the following public meeting entitled ``CBD and Other
Cannabinoids: Sex and Gender Differences in Use and Responses.'' The
purpose of the public meeting is to discuss potential sex (biological)
and gender (psychosocial) differences in use and responses to
cannabidiol (CBD) and other cannabinoids. Researchers, educators,
clinicians, and patients may benefit from attending this
multidisciplinary scientific conference on CBD and other cannabinoids.
Presentations will address patient and healthcare provider perspectives
on CBD and other cannabinoid use, sex differences in the effects of CBD
and other cannabinoids, use of CBD and other cannabinoids in pregnancy,
and government agency perspectives on CBD research and evaluation.

DATES: The public meeting will be held on November 19, 2020, from 9
a.m. to 4 p.m. Eastern Time and will take place virtually by webcast
only. Registration to attend the meeting and other information can be
found at https://www.fda.gov/science-research/womens-health-research/scientific-conference-cbd-and-other-cannabinoids-sex-and-gender-differences-use-and-responses. See the SUPPLEMENTARY INFORMATION
section for registration date and information.

FOR FURTHER INFORMATION CONTACT: Lisa Lineberger, Food and Drug
Administration, Office of the Commissioner, Office of Women's Health,
Bldg. 32, Rm. 2333, 10903 New Hampshire Ave., Silver Spring, MD 20993,
301-796-8751<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    FDA is responsible for protecting the public health by assuring the
safety and efficacy of FDA-regulated products. Although CBD is widely
available and marketed as a component of products including drugs,
food, dietary supplements, cosmetics, and animal health products, FDA
has only approved one CBD product--a prescription drug to treat two
rare, severe forms of epilepsy. There is very limited available
information about CBD, including about its effects on the body.
    FDA recognizes the significant public interest in cannabis and
cannabis-derived compounds, particularly CBD. However, there are many
unanswered questions about the science, safety, and quality of products
containing CBD. The Agency is working on answering these questions
through ongoing efforts including feedback from a FDA hearing and
information and data gathering through a public docket. This public
meeting will provide further insight into the scientific evidence
suggesting the presence or absence of sex and gender differences in use
and responses to CBD and other cannabinoids. Conditions for which CBD
is often marketed, such as chronic pain, anxiety, depression, and sleep
disturbances, are more prevalent in women than men. Therefore,
consideration of issues pertaining to the safety of CBD products may be
particularly important to address in women. In addition, use of CBD and
other cannabinoids during pregnancy is an important public health
concern that will be highlighted at this meeting.

II. Topics for Discussion at the Public Meeting

    This public meeting will include presentations and panel
discussions by experts in the fields of cannabinoid research,
education, and clinical care about potential biological (sex) and
psychosocial (gender) differences in the use and effects of CBD and
other cannabinoids. Each panel discussion will include a Q&A session to
respond to questions from attendees.
    We will make the agenda and materials for the public meeting
available online by November 12, 2020, at https://www.fda.gov/science-research/womens-health-research/scientific-conference-cbd-and-other-cannabinoids-sex-and-gender-differences-use-and-responses.

III. Participating in the Public Meeting

    Registration: To register for the public meeting, please visit the
following website: https://collaboration.fda.gov/owh-cbd-meeting/event/registration.html. Please provide complete contact information for each
attendee, including name, title, affiliation, address, email, and
telephone.
    Persons interested in attending this public meeting must register
online by November 16, 2020, 5 p.m. Eastern Time. Registrants will
receive confirmation when they have been accepted.
    If you need special accommodations due to a disability, please
contact Lisa Lineberger at<PHONE_NUMBER> or<EMAIL_ADDRESS>no
later than November 9, 2020.
    Streaming webcast of the public meeting: The webcast for this
meeting will be available to registrants. If you have never attended a
Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a
quick overview of the Connect Pro program, visit https://www.adobe.com/go/connectpro_overview. FDA has verified the website addresses in this
document, as of the date this document publishes in the Federal
Register, but websites are subject to change over time.

    Dated: September 15, 2020.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2020-21023 Filed 9-22-20; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 86, Number 178 (Friday, September 17, 2021)]
[Notices]
[Page 51885]
[FR Doc No: 2021-20119]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-9058-4]

Environmental Impact Statements; Notice of Availability

    Responsible Agency: Office of Federal Activities, General
Information<PHONE_NUMBER> or https://www.epa.gov/nepa.

Weekly receipt of Environmental Impact Statements (EIS)
Filed September 3, 2021 10 a.m. EST Through September 13, 2021 10 a.m.
EST
Pursuant to 40 CFR 1506.9.

Notice

    Section 309(a) of the Clean Air Act requires that EPA make public
its comments on EISs issued by other Federal agencies. EPA's comment
letters on EISs are available at: https://cdxnodengn.epa.gov/cdx-enepa-public/action/eis/search.

EIS No. 20210137, Fourth Final Supplemental, FHWA, VT, Champlain
Parkway/Southern Connector Burlington Vermont, Review Period Ends: 10/
18/2021, Contact: Patrick Kirby<PHONE_NUMBER>.
EIS No. 20210138, Draft, USCG, PRO, Offshore Patrol Cutter Acquisition
Program, Comment Period Ends: 11/01/2021, Contact: Andrew Haley 202-
372-1821.
EIS No. 20210139, Final, USMC, USAF, AZ, Extension of the Barry M.
Goldwater Range Land Withdrawal and Proposed Gila Bend Addition Land
Withdrawal, Review Period Ends: 10/18/2021, Contact: Jon Haliscak 210-
395-0615.
EIS No. 20210140, Draft, BLM, UT, Pine Valley Water Supply Project,
Comment Period Ends: 11/01/2021, Contact: Brooklynn Cox<PHONE_NUMBER>.

    Dated: September 13, 2021.
Candi Schaedle,
Acting Director, NEPA Compliance Division, Office of Federal
Activities.
[FR Doc. 2021-20119 Filed 9-16-21; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 85, Number 97 (Tuesday, May 19, 2020)]
[Notices]
[Page 30007]
[FR Doc No: 2020-10689]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2020-0087]

Qualification of Drivers; Exemption Applications; Implantable
Cardioverter Defibrillators

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of correction; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: FMCSA corrects the State of domicile for one individual listed
in its April 15, 2020, notice requesting comments on the receipt of
applications from five individuals for an exemption from the
prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs)
against operation of a commercial motor vehicle (CMV) by persons with a
current clinical diagnosis of myocardial infarction, angina pectoris,
coronary insufficiency, thrombosis, or any other cardiovascular disease
of a variety known to be accompanied by syncope (transient loss of
consciousness), dyspnea (shortness of breath), collapse, or congestive
heart failure. The Agency also extends the public comment period for
that notice.

DATES: This correction is effective May 19, 2020. The comment period
for the notice published April 15, 2020, at 85 FR 21061, is extended by
30 days. Comments must be received on or before June 15, 2020.

ADDRESSES: You may submit comments identified by the Federal Docket
Management System (FDMS) Docket ID FMCSA-2020-0087 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov/docket?D=FMCSA-2020-0087. Follow the online
instructions for submitting comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m.,
ET, Monday through Friday, except Federal Holidays.
     Fax:<PHONE_NUMBER>.
    To avoid duplication, please use only one of these four methods.
See the ``Public Participation'' portion of the SUPPLEMENTARY
INFORMATION section for instructions on submitting comments.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Operations,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: On April 15, 2020, (85 FR 21061), FMCSA
published a notice regarding five individuals requesting an exemption
from the physical qualification standard found in Sec.  391.41(b)(4),
which states that a person is physically qualified to drive a CMV if
that person has no current clinical diagnosis of myocardial infarction,
angina pectoris, coronary insufficiency, thrombosis, or any other
cardiovascular disease of a variety known to be accompanied by syncope,
dyspnea, collapse, or congestive cardiac failure. The notice
referenced, in error, Minnesota as the State of domicile for the
applicant, Theodore J. Engelke. Mr. Engelke's correct State of domicile
is Wisconsin.
    In addition, FMCSA extends the comment period to ensure that
interested parties have sufficient time to review and comment on the
exemption applications.

Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020-10689 Filed 5-18-20; 8:45 am]
BILLING CODE 4910-EX-P


[Federal Register Volume 85, Number 213 (Tuesday, November 3, 2020)]
[Notices]
[Pages 69619-69620]
[FR Doc No: 2020-24327]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP21-5-000]

Natural Gas Pipeline Company of America, LLC; Notice of
Application and Establishing Intervention Deadline

    Take notice that on October 8, 2020, Natural Gas Pipeline Company
of America LLC (Natural), 3250 Lacey Road, 7th Floor, Downers Grove,
Illinois 60515-7918, filed an application under section 7(b) and 7(c)
of the Natural Gas Act (NGA), and Part 157 of the Commission's
regulations requesting from the Commission an order granting: (1)
Permission and approval to abandon Natural's lease and operation of
certain transmission facilities from The Peoples Gas Light and Coke
Company (Peoples) in Calumet Area of the City of Chicago in Cook
County, Illinois (City); and (2) a certificate of public convenience
and necessity to authorize Natural to continue to lease, operate, and
maintain certain transmission facilities owned by Peoples in the
Crawford and Calumet Areas in the City that were leased under a 2006
lease agreement between Natural and Peoples, under a new amended and
restated lease agreement between Natural and Peoples. Natural states
that Natural currently leases from Peoples, pursuant to a lease
agreement between Natural and Peoples dated April 5, 2006, certain
facilities located in the City that are used to provide service to
certain of Natural's shippers. Natural states that following a notice
of termination from Peoples, Natural and Peoples entered into an
amended and restated lease agreement, dated October 7, 2020, that
reflects the removal and discontinuation of the Calumet Area facilities
from the lease arrangement and noted that the lease of property in the
Crawford Area remains unchanged, all as more fully set forth in the
application which is on file with the Commission and open for public
inspection.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (http://ferc.gov) using the
``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room, due to the proclamation declaring a National Emergency
concerning the Novel Coronavirus Disease (COVID-19), issued by the
President on March 13, 2020. For assistance, contact the Federal Energy
Regulatory Commission at<EMAIL_ADDRESS>or call toll-free,
(886) 208-3676 or TYY,<PHONE_NUMBER>.
    Any questions regarding the proposed project should be directed to
Kevin L. Palmer, Director, Natural Gas Pipeline Company of America LLC,
3250 Lacey Road, Suite 700, Downers Grove, Illinois 60515-7918, by
phone at<PHONE_NUMBER>, or by email at<EMAIL_ADDRESS>    Pursuant to Section 157.9 of the Commission's Rules of Practice and
Procedure,\1\ within 90 days of this Notice the Commission staff will
either: Complete its environmental review and place it into the
Commission's public record (eLibrary) for this proceeding; or issue a
Notice of Schedule for Environmental Review. If a Notice of Schedule
for Environmental Review is issued, it will indicate, among other
milestones, the anticipated date for the Commission staff's issuance of
the final environmental impact statement (FEIS) or environmental
assessment (EA) for this proposal. The filing of an EA in the
Commission's public record for this proceeding or the issuance of a
Notice of Schedule for Environmental Review will serve to notify
federal and state agencies of the timing for the completion of all
necessary reviews, and the subsequent need to complete all federal
authorizations within 90 days of the date of issuance of the Commission
staff's FEIS or EA.
---------------------------------------------------------------------------

    \1\ 18 CFR (Code of Federal Regulations) Sec.  157.9.
---------------------------------------------------------------------------

Public Participation

    There are two ways to become involved in the Commission's review of
this project: You can file comments on the project, and you can file a
motion to intervene in the proceeding. There is no fee or cost for
filing comments or intervening. The deadline for filing a motion to
intervene is 5:00 p.m. Eastern Time on November 10, 2020.

Comments

    Any person wishing to comment on the project may do so. Comments
may include statements of support or objections to the project as a
whole or specific aspects of the project. The more specific your
comments, the more useful they will be. To ensure that your comments
are timely and properly recorded, please submit your comments on or
before November 10, 2020.
    There are three methods you can use to submit your comments to the
Commission. In all instances, please reference the Project docket
number CP21-5-000 in your submission.
    (1) You may file your comments electronically by using the eComment
feature, which is located on the Commission's website at www.ferc.gov
under the link to Documents and Filings. Using eComment is an easy
method for interested persons to submit brief, text-only comments on a
project;
    (2) You may file your comments electronically by using the eFiling
feature, which is located on the Commission's website (www.ferc.gov)
under the link to Documents and Filings. With eFiling, you can provide
comments in a variety of formats by attaching them as a file with your
submission. New eFiling users must first create an account by clicking
on ``eRegister.'' You will be asked to select the type of filing you
are making; first select ``General'' and then select ``Comment on a
Filing''; or
    (3) You can file a paper copy of your comments by mailing them to
the following address below.\2\ Your written comments must reference
the Project docket number (CP21-5-000).
---------------------------------------------------------------------------

    \2\ Hand delivered submissions in docketed proceedings should be
delivered to Health and Human Services, 12225 Wilkins Avenue,
Rockville, Maryland 20852.

Kimberly D. Bose, Secretary, Federal Energy Regulatory Commission, 888
---------------------------------------------------------------------------
First Street NE, Washington, DC 20426

    The Commission encourages electronic filing of comments (options 1
and 2 above) and has eFiling staff available to assist you at (202)
502-8258 or [email protected]
    Persons who comment on the environmental review of this project
will be placed on the Commission's environmental mailing list, and will
receive notification when the environmental documents (EA or EIS) are
issued for this project and will be notified of meetings associated
with the Commission's environmental review process.
    The Commission considers all comments received about the project in
determining the appropriate action to be taken. However, the filing of
a comment alone will not serve to make the filer a party to the
proceeding. To become a party, you must intervene in the proceeding.
For instructions on how to intervene, see below.

Interventions

    Any person, which includes individuals, organizations, businesses,
municipalities, and other entities,\3\ has

the option to file a motion to intervene in this proceeding. Only
intervenors have the right to request rehearing of Commission orders
issued in this proceeding and to subsequently challenge the
Commission's orders in the U.S. Circuit Courts of Appeal.
---------------------------------------------------------------------------

    \3\ 18 CFR 385.102(d).
---------------------------------------------------------------------------

    To intervene, you must submit a motion to intervene to the
Commission in accordance with Rule 214 of the Commission's Rules of
Practice and Procedure \4\ and the regulations under the NGA \5\ by the
intervention deadline for the project, which is November 10, 2020. As
described further in Rule 214, your motion to intervene must state, to
the extent known, your position regarding the proceeding, as well as
your interest in the proceeding. [For an individual, this could include
your status as a landowner, ratepayer, resident of an impacted
community, or recreationist. You do not need to have property directly
impacted by the project in order to intervene.] For more information
about motions to intervene, refer to the FERC website at https://www.ferc.gov/resources/guides/how-to/intervene.asp.
---------------------------------------------------------------------------

    \4\ 18 CFR 385.214.
    \5\ 18 CFR 157.10.
---------------------------------------------------------------------------

    There are two ways to submit your motion to intervene. In both
instances, please reference the Project docket number CP21-5-000 in
your submission.
    (1) You may file your motion to intervene by using the Commission's
eFiling feature, which is located on the Commission's website
(www.ferc.gov) under the link to Documents and Filings. New eFiling
users must first create an account by clicking on ``eRegister.'' You
will be asked to select the type of filing you are making; first select
``General'' and then select ``Intervention.'' The eFiling feature
includes a document-less intervention option; for more information,
visit https://www.ferc.gov/docs-filing/efiling/document-less-intervention.pdf; or
    (2) You can file a paper copy of your motion to intervene, along
with three copies, by mailing the documents to the address below.\6\
Your motion to intervene must reference the Project docket number CP21-
5-000.
---------------------------------------------------------------------------

    \6\ Hand delivered submissions in docketed proceedings should be
delivered to Health and Human Services, 12225 Wilkins Avenue,
Rockville, Maryland 20852.

Kimberly D. Bose, Secretary, Federal Energy Regulatory Commission, 888
---------------------------------------------------------------------------
First Street NE, Washington, DC 20426

    The Commission encourages electronic filing of motions to intervene
(option 1 above) and has eFiling staff available to assist you at (202)
502-8258 or [email protected]
    Motions to intervene must be served on the applicant either by mail
or email at: 3250 Lacey Road, Suite 700, Downers Grove, Illinois 60515-
7918 or at<EMAIL_ADDRESS>Any subsequent submissions by
an intervenor must be served on the applicant and all other parties to
the proceeding. Contact information for parties can be downloaded from
the service list at the eService link on FERC Online. Service can be
via email with a link to the document.
    All timely, unopposed \7\ motions to intervene are automatically
granted by operation of Rule 214(c)(1).\8\ Motions to intervene that
are filed after the intervention deadline are untimely, and may be
denied. Any late-filed motion to intervene must show good cause for
being late and must explain why the time limitation should be waived
and provide justification by reference to factors set forth in Rule
214(d) of the Commission's Rules and Regulations.\9\ A person obtaining
party status will be placed on the service list maintained by the
Secretary of the Commission and will receive copies (paper or
electronic) of all documents filed by the applicant and by all other
parties.
---------------------------------------------------------------------------

    \7\ The applicant has 15 days from the submittal of a motion to
intervene to file a written objection to the intervention.
    \8\ 18 CFR 385.214(c)(1).
    \9\ 18 CFR 385.214(b)(3) and (d).
---------------------------------------------------------------------------

Tracking the Proceeding

    Throughout the proceeding, additional information about the project
will be available from the Commission's Office of External Affairs, at
(866) 208-FERC, or on the FERC website at www.ferc.gov using the
``eLibrary'' link as described above. The eLibrary link also provides
access to the texts of all formal documents issued by the Commission,
such as orders, notices, and rulemakings.
    In addition, the Commission offers a free service called
eSubscription which allows you to keep track of all formal issuances
and submittals in specific dockets. This can reduce the amount of time
you spend researching proceedings by automatically providing you with
notification of these filings, document summaries, and direct links to
the documents. For more information and to register, go to
www.ferc.gov/docs-filing/esubscription.asp.
    Intervention Deadline: 5:00 p.m. Eastern Time on November 10, 2020.

    Dated: October 27, 2020.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2020-24327 Filed 11-2-20; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 226 (Friday, November 25, 2022)]
[Rules and Regulations]
[Pages 72377-72379]
[FR Doc No: 2022-25512]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2022-1064; Project Identifier MCAI-2022-00342-T;
Amendment 39-22224; AD 2022-22-09]
RIN 2120-AA64

Airworthiness Directives; Airbus SAS Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The FAA is adopting a new airworthiness directive (AD) for
certain Airbus SAS Model A350-1041 airplanes. This AD was prompted by a
report of rejected take-offs after transient engine N1 shaft speed
exceedance. This AD requires replacing certain hydro-mechanical units
(HMUs) with serviceable HMUs before reaching a reduced life limit, as
specified in a European Union Aviation Safety Agency (EASA) AD, which
is incorporated by reference. This AD also limits the installation of
affected parts under certain conditions. The FAA is issuing this AD to
address the unsafe condition on these products.

DATES: This AD is effective December 30, 2022.
    The Director of the Federal Register approved the incorporation by
reference of a certain publication listed in this AD as of December 30,
2022.

ADDRESSES:
    AD Docket: You may examine the AD docket at regulations.gov under
Docket No. FAA-2022-1064; or in person at Docket Operations between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD
docket contains this final rule, the mandatory continuing airworthiness
information (MCAI), any comments received, and other information. The
address for Docket Operations is U.S. Department of Transportation,
Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200
New Jersey Avenue SE, Washington, DC 20590.
    Material Incorporated by Reference:
     For material incorporated by reference in this AD, contact
EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221
8999 000; email [email protected]; website easa.europa.eu. You may
find this material on the EASA website at ad.easa.europa.eu.
     You may view this material at the FAA, Airworthiness
Products Section, Operational Safety Branch, 2200 South 216th St., Des
Moines, WA. For information on the availability of this material at the
FAA, call<PHONE_NUMBER>. It is also available in the AD docket at
regulations.gov under Docket No. FAA-2022-1064.

FOR FURTHER INFORMATION CONTACT: Dat Le, Aerospace Engineer, Large
Aircraft Section, FAA, International Validation Branch, 2200 South
216th St., Des Moines, WA 98198; telephone<PHONE_NUMBER>; email
[email protected].

SUPPLEMENTARY INFORMATION:

Background

    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14
CFR part 39 by adding an AD that would apply to certain Airbus SAS
Model A350-1041 airplanes. The NPRM published in the Federal Register
on August 29, 2022 (87 FR 52705). The NPRM was prompted by AD 2022-
0040, dated March 8, 2022, issued by EASA, which is the Technical Agent
for the Member States of the European Union (EASA AD 2022-0040)
(referred to after this as the MCAI). The MCAI states that rejected
take-offs after transient engine N1 shaft speed exceedance have been
reported. The MCAI adds that the combining spill valve (CSV) of the
engine HMU was slow to close due to piston wear. A worn CSV piston does
not move fully and freely over its operating range, and when it moves
to the fully closed position, an excess of fuel is sent to the fuel
nozzles, which eventually results in an N1 transient shaft overspeed. A
stuck CSV piston could significantly reduce engine thrust, and if
combined with a loss of the second engine, could possibly result in
reduced control of the airplane.
    In the NPRM, the FAA proposed to require replacing certain HMUs
with serviceable HMUs before reaching a reduced life limit, as
specified in EASA AD 2022-0040. The NPRM also proposed to limit the
installation of affected parts under certain conditions. The FAA is
issuing this AD to address the unsafe condition on these products.
    You may examine the MCAI in the AD docket at regulations.gov under
Docket No. FAA-2022-1064.

Discussion of Final Airworthiness Directive

Comments

    The FAA received comments from the Air Line Pilots Association,
International (ALPA) who supported the NPRM without change.

Conclusion

    This product has been approved by the aviation authority of another
country and is approved for operation in the United States. Pursuant to
the FAA's bilateral agreement with this State of Design Authority, it
has notified the FAA of the unsafe condition described in the MCAI
referenced above. The FAA reviewed the relevant data, considered the
comment received, and determined that air safety requires adopting this
AD as proposed. Accordingly, the FAA is issuing this AD to address the
unsafe condition on this product. Except for minor editorial changes,
this AD is adopted as proposed in the NPRM. None of the changes will
increase the economic burden on any operator.

Related Service Information Under 1 CFR Part 51

    EASA AD 2022-0040 specifies procedures for replacing each HMU
having part number G5020HMU02 with a serviceable HMU before reaching a
reduced life limit. EASA AD 2022-0040 also limits the installation of
affected parts under certain conditions. This material is reasonably
available because the interested parties have access to it through
their normal course of business or by the means identified in the
ADDRESSES section.

Interim Action

    The FAA considers that this AD is an interim action. If final
action is later identified, the FAA might consider further rulemaking
then.

Costs of Compliance

    The FAA estimates that this AD affects 29 airplanes of U.S.
registry. The FAA estimates the following costs to comply with this AD:

                                      Estimated Costs for Required Actions
----------------------------------------------------------------------------------------------------------------
                                                                                Cost per       Cost on U.S.
                          Labor cost                              Parts cost        product         operators
----------------------------------------------------------------------------------------------------------------
7 work-hours x $85 per hour = $595...........................            $0 *             $595          $17,255
----------------------------------------------------------------------------------------------------------------
* The FAA has received no definitive data on which to base the cost estimates for the parts specified in this
  AD.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: General requirements.
Under that section, Congress charges the FAA with promoting safe flight
of civil aircraft in air commerce by prescribing regulations for
practices, methods, and procedures the Administrator finds necessary
for safety in air commerce. This regulation is within the scope of that
authority because it addresses an unsafe condition that is likely to
exist or develop on products identified in this rulemaking action.

Regulatory Findings

    This AD will not have federalism implications under Executive Order
13132. This AD will not have a substantial direct effect on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government.
    For the reasons discussed above, I certify that this AD:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Will not affect intrastate aviation in Alaska, and
    (3) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new airworthiness
directive:

2022-22-09 Airbus SAS: Amendment 39-22224; Docket No. FAA-2022-1064;
Project Identifier MCAI-2022-00342-T.

(a) Effective Date

    This airworthiness directive (AD) is effective December 30,
2022.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to Airbus SAS Model A350-1041 airplanes,
certificated in any category, as identified in European Union
Aviation Safety Agency (EASA) AD 2022-0040, dated March 8, 2022
(EASA AD 2022-0040).

(d) Subject

    Air Transport Association (ATA) of America Code 73, Engine Fuel
and Control.

(e) Unsafe Condition

    This AD was prompted by a report of rejected take-offs after
transient engine N1 shaft speed exceedance. The FAA is issuing this
AD to address a stuck combined spill valve (CSV) piston of the
engine hydro-mechanical units (HMUs), which could significantly
reduce engine thrust, and if combined with a loss of the second
engine, could possibly result in reduced control of the airplane.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Requirements

    Except as specified in paragraph (h) of this AD: Comply with all
required actions and compliance times specified in, and in
accordance with, EASA AD 2022-0040.

(h) Exceptions to EASA AD 2022-0040

    (1) Where EASA AD 2022-0040 refers to its effective date, this
AD requires using the effective date of this AD.
    (2) The ``Remarks'' section of EASA AD 2022-0040 does not apply
to this AD.
    (3) Where paragraph (1) of EASA AD 2022-0040 specifies to
replace ``[b]efore an affected part exceeds the life limit as
defined in Table 1 of this [EASA] AD,'' this AD requires replacing
``before an affected part exceeds the life limit specified in Table
1 of EASA 2022-0040, or within 3 flight cycles after the effective
date of this AD, whichever occurs later.''
    (4) Where Table 1 of EASA AD 2022-0040 specifies calendar
timeframes, for this AD replace the text ``31 March 2022 to 29, June
2023'' with ``the effective date of this AD through June 29, 2023.''

(i) Additional AD Provisions

    The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
International Validation Branch, FAA, has the authority to approve
AMOCs for this AD, if requested using the procedures found in 14 CFR
39.19. In accordance with 14 CFR 39.19, send your request to your
principal inspector or responsible Flight Standards Office, as
appropriate. If sending information directly to the International
Validation Branch, send it to the attention of the person identified
in paragraph (j) of this AD. Information may be emailed to: [email protected]. Before using any approved AMOC, notify your
appropriate principal inspector, or lacking a principal inspector,
the manager of the responsible Flight Standards Office.
    (2) Contacting the Manufacturer: For any requirement in this AD
to obtain instructions from a manufacturer, the instructions must be
accomplished using a method approved by the Manager, Large Aircraft
Section, International Validation Branch, FAA; or EASA; or Airbus
SAS's EASA Design Organization Approval (DOA). If approved by the
DOA, the approval must include the DOA-authorized signature.
    (3) Required for Compliance (RC): Except as required by
paragraph (i)(2) of this AD, if any service information referenced
in EASA AD 2022-0042 contains paragraphs that are labeled as RC, the
instructions in RC paragraphs, including subparagraphs under an RC
paragraph, must be done to comply with this AD; any paragraphs,
including subparagraphs under those paragraphs, that are not
identified as RC are recommended. The instructions in paragraphs,
including subparagraphs under those paragraphs, not identified as RC
may be deviated from using accepted methods in accordance with the
operator's maintenance or inspection program without obtaining
approval of an AMOC, provided the instructions identified as RC can
be done and the airplane can be put back in an airworthy condition.
Any substitutions or changes to instructions identified as RC
require approval of an AMOC.

(j) Additional Information

    For more information about this AD, contact Dat Le, Aerospace
Engineer, Large Aircraft Section, FAA, International Validation
Branch, 2200 South 216th St., Des Moines, WA 98198; telephone 516-
228-7317; email [email protected].

(k) Material Incorporated by Reference

    (1) The Director of the Federal Register approved the
incorporation by reference of the service information listed in this
paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.
    (2) You must use this service information as applicable to do
the actions required by this AD, unless this AD specifies otherwise.
    (i) European Union Aviation Safety Agency (EASA) AD 2022-0040,
dated March 8, 2022.
    (ii) [Reserved]
    (3) For EASA AD 2022-0040, contact EASA, Konrad-Adenauer-Ufer 3,
50668 Cologne, Germany; telephone +49 221 8999 000; email
[email protected]; website easa.europa.eu. You may find this EASA
AD on the EASA website at ad.easa.europa.eu.
    (4) You may view this material at the FAA, Airworthiness
Products Section, Operational Safety Branch, 2200 South 216th St.,
Des Moines, WA. For information on the availability of this material
at the FAA, call<PHONE_NUMBER>.
    (5) You may view this material that is incorporated by reference
at the National

Archives and Records Administration (NARA). For information on the
availability of this material at NARA, email [email protected],
or go to: www.archives.gov/federal-register/cfr/ibr-locations.html.

    Issued on October 21, 2022.
Christina Underwood,
Acting Director, Compliance & Airworthiness Division, Aircraft
Certification Service.
[FR Doc. 2022-25512 Filed 11-23-22; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 84, Number 171 (Wednesday, September 4, 2019)]
[Notices]
[Pages 46520-46521]
[FR Doc No: 2019-19098]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-9999-25-Region 2]

Proposed CERCLA Cost Recovery Settlement Regarding the Lightman
Drum Company Superfund Site, Camden County, New Jersey

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice; request for public comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Comprehensive Environmental Response,
Compensation, and Liability Act of 1980, as amended (``CERCLA''),
notice is hereby given by the U.S. Environmental Protection Agency
(``EPA''), Region 2, of a proposed cost recovery settlement agreement
pursuant to CERCLA between EPA and Air Products and Chemicals, Inc.;
Alco Industries Inc.; Bayer CropScience, Inc.; Colonial Heights
Packaging Inc.; Continental Holdings Inc.; Croda Inks Corp.; Forenco,
Inc.; Henkel US Operations Corporation, for itself and on behalf of
Amchem Products, Inc,; LANXESS Sybron Chemicals, Inc.; Reynolds Metals
Company, LLC; The Hillshire Brands Company; Sonoco Products Company;
Stepan Company; Union Carbide Corporation; and USG Corporation
(``Settling Parties'') regarding the Lightman Drum Company Superfund
Site, Winslow Township, Camden County, New Jersey (``Site''). Pursuant
to the proposed cost recovery settlement agreement, the Settling
Parties will pay $13,526.88 to resolve the Settling Parties' civil
liability under Section 107(a) of CERCLA for past response costs and
will pay future response costs for the Site.

DATES: Comments must be submitted on or before October 4, 2019.

ADDRESSES: The proposed settlement agreement is available for public
inspection at EPA's Region 2 offices. To request a copy of the proposed
settlement agreement, please contact the EPA employee identified in the
FOR FURTHER INFORMATION CONTACT section below.

FOR FURTHER INFORMATION CONTACT: Amelia Wagner, Assistant Regional
Counsel, U.S. Environmental Protection Agency, Region 2, Office of
Regional Counsel, 290 Broadway-17th Floor, New York, New York 10007-
1866. Email<EMAIL_ADDRESS>Telephone:<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: For 30 days following the date of
publication of this notice, EPA will receive written comments
concerning the proposed cost recovery settlement agreement. Comments to
the proposed settlement agreement should reference the Lightman Drum
Company Superfund Site, U.S. EPA Index No. CERCLA-02-2019-2004. EPA
will consider all comments received during the 30-day public comment
period and may modify or withdraw its consent to the settlement
agreement if comments received disclose facts or considerations that
indicate that the proposed settlement agreement is inappropriate,
improper, or inadequate. EPA's

response to comments will be available for public inspection at EPA's
Region 2 offices located at 290 Broadway, New York, NY 10007-1866.

    Dated: August 6, 2019.
Pat Evangelista,
Acting Director, Superfund and Emergency Management Division, Region 2.
[FR Doc. 2019-19098 Filed 9-3-19; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register: April 27, 2006 (Volume 71, Number 81)]
[Notices]
[Page 24845]
[DOCID:fr27ap06-32]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP96-200-149]

CenterPoint Energy Gas Transmission Company; Notice of Negotiated
Rate Filing

April 20, 2006.
    Take notice that on March 30, 2006, CenterPoint Energy Gas
Transmission Company (CEGT) tendered for filing and approval two
negotiated rate agreements, one between CEGT and Oneok Energy Services
Company, LP, and one between CEGT and Coral Energy Resources, L.P. CEGT
has entered into agreements to provide parking service to these
shippers under Rate Schedule PHS to be effective April 1, 2006.
    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211 and 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed in accordance with the provisions of
Section 154.210 of the Commission's regulations (18 CFR 154.210).
Anyone filing an intervention or protest must serve a copy of that
document on the Applicant. Anyone filing an intervention or protest on
or before the intervention or protest date need not serve motions to
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov.
 Persons unable to file electronically should submit an

original and 14 copies of the protest or intervention to the Federal
Energy Regulatory Commission, 888 First Street, NE., Washington, DC
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the

``eLibrary'' link and is available for review in the Commission's
Public Reference Room in Washington, DC. There is an ``eSubscription''
link on the Web site that enables subscribers to receive e-mail
notification when a document is added to a subscribed docket(s). For
assistance with any FERC Online service, please e-mail
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For

TTY, call<PHONE_NUMBER>.

Magalie R. Salas,
Secretary.
 [FR Doc. E6-6323 Filed 4-26-06; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 76, Number 144 (Wednesday, July 27, 2011)]
[Notices]
[Pages 44903-44904]
[FR Doc No: 2011-18912]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP11-503-000]

Kinder Morgan Interstate Gas Transmission, LLC; Notice of Request
Under Blanket Authorization

    Take notice that on June 30, 2011 Kinder Morgan Interstate Gas
Transmission, LLC (KMIGT), Post Office Box 281304, Lakewood, Colorado
80228, filed in Docket No. CP11-503-000, a Prior Notice request
pursuant to sections 157.205 and 157.216 of the Commission's
Regulations under the Natural Gas Act for authorization to abandon its
Cozad South Compressor Station located in Dawson County, Nebraska.
Specifically, KMIGT proposes to abandon by removal the existing two 500
HP compressor units with appurtenances, station piping, buildings and
auxiliary equipment. KMIGT asserts that the proposed abandonment will
not have any adverse effect on the services it provides and will not
impact KMIGT's customers, all as more fully set forth in the
application which is on file with the Commission and open to public
inspection. The filing may also be viewed on the web at http://www.ferc.gov using the ``eLibrary'' link. Enter the docket number
excluding the last three digits in the docket number field to access
the document. For assistance, contact FERC at
<EMAIL_ADDRESS>or call toll-free,<PHONE_NUMBER> or TTY,
(202) 502-8659.

    Any questions regarding this Application should be directed to
Kelly Allen, Manager, Certificates and Reporting, Transwestern Pipeline
Company, LLC, 711 Louisiana Street, Suite 900, Houston, Texas, 77002,
or call<PHONE_NUMBER>, or fax<PHONE_NUMBER>, or by e-mail:
<EMAIL_ADDRESS>    Any person may, within 60 days after the issuance of the instant
notice by the Commission, file pursuant to Rule 214 of the Commission's
Procedural Rules (18 CFR 385.214) a motion to intervene or notice of
intervention. Any person filing to intervene or the Commission's staff
may, pursuant to section 157.205 of the Commission's Regulations under
the NGA (18 CFR 157.205) file a protest to the request. If no protest
is filed within the time allowed therefore, the proposed activity shall
be deemed to be authorized effective the day after the time allowed for
protest. If a protest is filed and not withdrawn within 30 days after
the time allowed for filing a protest, the instant request shall be
treated as an application for authorization pursuant to section 7 of
the NGA.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commenter's will be
placed on the Commission's environmental mailing list, will receive
copies of the environmental documents, and will be notified of meetings
associated with he Commission's environmental review process.
Environmental commenter's will not be required to serve copies of filed
documents on all other parties. However, the non-party commentary, will
not receive copies of all documents filed by other parties or issued by
the Commission (except for the mailing of environmental documents
issued by the Commission) and ill not have the right to seek court
review of the Commission's final order.
    The Commission strongly encourages electronic filings of comments,
protests, and interventions via the internet in lieu of paper. See 18
CFR 385.2001(a) (1) (iii) and the instructions on the Commission's Web
site (http://www.ferc.gov) under the ``e-Filing'' link.

    Dated: July 13, 2011.
Kimberly D. Bose,
Secretary.
[FR Doc. 2011-18912 Filed 7-26-11; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 86, Number 169 (Friday, September 3, 2021)]
[Notices]
[Pages 49546-49548]
[FR Doc No: 2021-19024]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-N-0897]

Oncologic Drugs Advisory Committee; Notice of Meeting;
Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Oncologic Drugs Advisory
Committee. The general function of the committee is to provide advice
and recommendations to FDA on regulatory issues. The meeting will be
open to the public. FDA is establishing a docket for public comment on
this document.

DATES: The meeting will be held on October 28, 2021, from 10:30 a.m. to
3 p.m. Eastern Time.

ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions about FDA advisory committee meetings may be
accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2021-N-0897. The docket will close on October
27, 2021. Submit either electronic or written comments on this public
meeting by October 27, 2021. Please note that late, untimely filed
comments will not be considered. Electronic comments must be submitted
on or before October 27, 2021. The https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of October 27, 2021. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.
    Comments received on or before October 14, 2021, will be provided
to the committee. Comments received after that date will be taken into
consideration by FDA. In the event that the meeting is cancelled, FDA
will continue to evaluate any relevant applications or information, and
consider any comments submitted to the docket, as appropriate.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2021-N-0897 for ``Oncologic Drugs Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: She-Chia Chen, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 240-
402-5343, Fax:<PHONE_NUMBER><EMAIL_ADDRESS>or FDA Advisory
Committee Information Line, 1-800-741-8138<PHONE_NUMBER> in the
Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check FDA's website at
https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. The committee
will discuss new drug application (NDA) 214383, PEPAXTO (melphalan
flufenamide) for injection submitted by Oncopeptides AB, approved under
21 CFR 314.500 (subpart H, accelerated approval regulations), in
combination with dexamethasone for the treatment of adult patients with
relapsed or refractory multiple myeloma who have received at least four
prior lines of therapy and whose disease is refractory to at least one
proteasome inhibitor, one immunomodulatory agent, and one CD38-directed
monoclonal antibody.
    The committee will hear an update where the confirmatory trial
demonstrated a worse overall survival in the melphalan flufenamide
treatment arm compared to the control arm. Confirmatory studies are
post-marketing studies to verify and describe the clinical benefit of a
drug after it receives accelerated approval. Based on the update
provided, the committee will have a general discussion focused on next
steps for the product including whether the indication should remain on
the market while additional trial(s) are conducted.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available on FDA's website at
the time of the advisory committee meeting. Background material and the
link to the online teleconference meeting room will be available at
https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll
down to the appropriate advisory committee meeting link. The meeting
will include slide presentations with audio components to allow the
presentation of materials in a manner that most closely resembles an
in-person advisory committee meeting.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see
ADDRESSES) on or before October 14, 2021, will be provided to the
committee. Oral presentations from the public will be scheduled between
approximately 1 p.m. to 2 p.m. Eastern Time. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time

requested to make their presentation on or before October 5, 2021. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by October 6, 2021.
    For press inquiries, please contact the Office of Media Affairs at
<EMAIL_ADDRESS>or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact She-Chia Chen (see FOR FURTHER INFORMATION CONTACT) at least 7
days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: August 30, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-19024 Filed 9-2-21; 8:45 am]
BILLING CODE 4164-01-P